Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3260

1.

Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder.

Sellman DP, Peard L, Simpson G, Lancaster K, Kavuri S, Terris M, Madi R.

Urol Ann. 2018 Jul-Sep;10(3):342-344. doi: 10.4103/UA.UA_97_17.

2.

Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis.

Abdou AM, Ammar IMM, Alnemr AAA, Abdelrhman AA.

J Obstet Gynaecol India. 2018 Aug;68(4):306-313. doi: 10.1007/s13224-018-1119-3. Epub 2018 Apr 16.

PMID:
30065547
3.

The Use of Leuprolide Acetate in the Management of High-Risk Sex Offenders.

Gallo A, Abracen J, Looman J, Jeglic E, Dickey R.

Sex Abuse. 2018 Jul 26:1079063218791176. doi: 10.1177/1079063218791176. [Epub ahead of print]

PMID:
30047834
4.

Trends in the "Off-Label" Use of GnRH Agonists Among Pediatric Patients in the United States.

Lopez CM, Solomon D, Boulware SD, Christison-Lagay E.

Clin Pediatr (Phila). 2018 Jul 1:9922818787260. doi: 10.1177/0009922818787260. [Epub ahead of print]

PMID:
30003804
5.

Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP.

Cancer Res. 2018 Jun 19. pii: canres.0610.2018. doi: 10.1158/0008-5472.CAN-18-0610. [Epub ahead of print]

PMID:
29921690
6.

Bazedoxifene/conjugated estrogens in combination with leuprolide for the treatment of endometriosis.

Hill AM, Lessey B, Flores VA, Taylor HS.

Clin Case Rep. 2018 Apr 6;6(6):990-994. doi: 10.1002/ccr3.1501. eCollection 2018 Jun.

7.

Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.

Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Murakami N, Kitajima M, Kawakami A.

Int J Rheum Dis. 2018 Jun;21(6):1287-1292. doi: 10.1111/1756-185X.13318.

PMID:
29879312
8.

Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.

Bhandarkar NS, Kumar SA, Martin J, Brown L, Panchal SK.

Mar Drugs. 2018 May 24;16(6). pii: E182. doi: 10.3390/md16060182.

9.

Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data.

Smith MA, Bowen RL, Nguyen RQ, Perry G, Atwood CS, Rimm AA.

J Alzheimers Dis. 2018;63(4):1269-1277. doi: 10.3233/JAD-170847.

PMID:
29782310
10.

Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.

Klein KO, Dragnic S, Soliman AM, Bacher P.

J Pediatr Endocrinol Metab. 2018 Jun 27;31(6):655-663. doi: 10.1515/jpem-2017-0523.

PMID:
29750651
11.

Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.

Kendzierski DC, Schneider BP, Kiel PJ.

Clin Breast Cancer. 2018 Apr 18. pii: S1526-8209(17)30722-X. doi: 10.1016/j.clbc.2018.04.005. [Epub ahead of print]

PMID:
29747931
12.

Genistein modulates the estrogen receptor and suppresses angiogenesis and inflammation in the murine model of peritoneal endometriosis.

Sutrisno S, Aprina H, Simanungkalit HM, Andriyani A, Barlianto W, Sujuti H, Santoso S, Dwijayasa PM, Wahyuni ES, Mustofa E.

J Tradit Complement Med. 2017 Apr 25;8(2):278-281. doi: 10.1016/j.jtcme.2017.03.002. eCollection 2018 Apr.

13.

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men.

Smith TJ, Loprinzi CL, Deville C.

N Engl J Med. 2018 May 3;378(18):1745-1746. doi: 10.1056/NEJMc1801992. No abstract available.

14.

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.

Cherrier MM, Cross DJ, Higano CS, Minoshima S.

Prostate Cancer Prostatic Dis. 2018 Apr 27. doi: 10.1038/s41391-018-0037-x. [Epub ahead of print]

PMID:
29700388
15.

Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats.

Lee DS, Kim SJ, Choi GW, Lee YB, Cho HY.

Molecules. 2018 Apr 15;23(4). pii: E909. doi: 10.3390/molecules23040909.

16.

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer.

Kojima N, Yamasaki Y, Koh H, Miyashita M, Morita H.

Case Rep Obstet Gynecol. 2018 Jan 23;2018:4931852. doi: 10.1155/2018/4931852. eCollection 2018.

17.

Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.

Ishikawa K, Tanaka A, Kogame A, Watanabe T, Tagawa Y, Matsui H.

Eur J Pharmacol. 2018 Jun 5;828:126-134. doi: 10.1016/j.ejphar.2018.03.032. Epub 2018 Mar 23.

PMID:
29580912
18.

Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.

Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta AD.

J Pediatr Adolesc Gynecol. 2018 Aug;31(4):376-381. doi: 10.1016/j.jpag.2018.03.004. Epub 2018 Mar 15.

PMID:
29551430
19.

Appraising cervical mucus: a new approach to evaluating contraceptives.

Han L, Padua E, Edelman A, Jensen JT.

Eur J Contracept Reprod Health Care. 2018 Feb;23(1):78-83. doi: 10.1080/13625187.2018.1437134. Epub 2018 Feb 19.

PMID:
29457758
20.

Supplemental Content

Loading ...
Support Center